Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug IDE574 targets Hard-to-Treat cancers in early trial

NCT ID NCT07540572

Recruiting now Disease control Sponsor: IDEAYA Biosciences Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated Apr 30, 2026

Summary

This study tests a new drug called IDE574 in people with advanced solid tumors (like lung, prostate, and colorectal cancers) and a specific type of breast cancer (ER+, HER2-). The goal is to see if the drug is safe and can shrink tumors. About 160 participants will receive IDE574 alone or with another drug (fulvestrant). This is an early-phase trial, so the main focus is safety and finding the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • NEXT Texas LLC - Austin

    RECRUITING

    Austin, Texas, 78758, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - Dallas

    RECRUITING

    Dallas, Texas, 75039, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - Houston

    RECRUITING

    Houston, Texas, 77054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START NY

    ACTIVE_NOT_RECRUITING

    Lake Success, New York, 11042, United States

  • Start San Antonio, LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CASTRATION RESISTANT PROSTATE CANCER (CRPC) ER+, HER 2- BREAST CANCER MICROSATELLITE STABLE (MSS) COLORECTAL CARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC)